Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will disclose its fourth quarter and full-year 2020 financial results on March 1, 2021, after the Nasdaq closes. A conference call will follow at 4:30 p.m. E.T. to discuss the results and provide a corporate update. Investors can access the call at (844) 534-7313 for domestic or (574) 990-1451 for international, using passcode 9672289. Sarepta specializes in precision genetic medicine, particularly in DMD and gene therapies for various rare diseases, with over 40 programs in development.

Sarepta Therapeutics (NASDAQ:SRPT) announced the winners of its Rare Lessons lesson planning competition, awarding each of the four winners $2,500, along with an equal amount to their respective educational institutions. The competition aims to promote awareness of rare diseases and encourage diversity in K-12 classrooms. Winning lesson plans are available on sharemylesson.com. Sarepta's commitment to education comes alongside its leadership in precision genetic medicine, particularly in treating rare diseases.

Sarepta Therapeutics (NASDAQ:SRPT) announced on January 29, 2021, that it granted equity awards as an inducement for 26 new hires under its 2014 Employment Commencement Incentive Plan. The total options issued amounted to 20,565 shares, with an exercise price of $89.40, applying to the closing stock price on the grant date. Additionally, 7,760 restricted stock units (RSUs) were granted, which will vest over four years. This initiative aims to strengthen recruitment as Sarepta continues to lead in precision genetic medicine for rare diseases.

Sarepta Therapeutics and Genevant Sciences announced a collaboration to advance gene editing therapies for neuromuscular diseases. Under the agreement, Sarepta will have options for exclusive licenses to Genevant's lipid nanoparticle (LNP) delivery technology for four indications, including Duchenne muscular dystrophy. Genevant could receive $50 million in near-term payments and further milestone payments and royalties. The partnership aims to improve gene delivery using LNPs, enhancing the potential for effective treatments in genetic disorders.

Sarepta Therapeutics is set to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 10:00 a.m. E.T. The presentation will be followed by a Q&A session starting at 10:20 a.m. E.T. Interested parties can access the live webcast on Sarepta's investor relations page, where the session will also be archived for 90 days. Sarepta focuses on precision genetic medicine for rare diseases, with over 40 programs in development.

Sarepta Therapeutics announced top-line results for Study SRP-9001-102, assessing the investigational gene therapy SRP-9001 in patients with Duchenne muscular dystrophy. The study met its primary biological endpoint, showing a 28.1% mean micro-dystrophin protein expression at 12 weeks. However, it failed to achieve statistical significance on the primary functional endpoint of the NSAA total score at 48 weeks. Notably, participants aged 4-5 showed a significant improvement of 4.3 points in NSAA compared to placebo. No new safety signals were identified, supporting SRP-9001's favorable safety profile.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 11 new employees as part of its 2014 Employment Commencement Incentive Plan, approved by its Compensation Committee. A total of options for 4,525 shares and 1,720 restricted stock units (RSUs) were awarded, with options priced at $170.49 per share, reflecting the stock's closing price on the grant date (Dec 31, 2020). The options and RSUs will vest over a four-year period, contingent on continued employment. This move aims to attract talent in the field of precision genetic medicine.

Sarepta Therapeutics has announced key executive appointments, including Ian Estepan as chief financial officer, Dallan Murray as chief commercial officer, and Louise Rodino-Klapac, Ph.D., as chief scientific officer. These changes aim to strengthen the leadership team and enhance operational efficiency. Ty Howton will retire as general counsel, with Ryan Brown stepping in as interim general counsel. Estepan's previous experience in corporate strategy and capital acquisition, along with Murray's commercial expertise, positions them to drive Sarepta's growth in genetic medicine.

Sarepta Therapeutics (NASDAQ:SRPT) announced promising results from its Phase 2 MOMENTUM study (Study 5051-201) for SRP-5051, a treatment for Duchenne muscular dystrophy (DMD) aimed at exon 51 skipping. The trial showed that a dose of 20 mg/kg led to significantly improved tissue exposure, exon skipping, and dystrophin production, with results noted after just 12 weeks. SRP-5051 was well-tolerated across all doses, supporting continued clinical development. Comparatively, SRP-5051 demonstrated superior efficacy over eteplirsen with a lower dose exposure, making it a potential game-changer in DMD treatment.